| Medical and Health Sciences | Lifetime | 479 | US 260 | 99.98 |
| Oncology | Lifetime | 39 | US 22 | 99.93 |
| Cancer Research | Lifetime | 138 | US 72 | 99.23 |
| Internal Medicine | Lifetime | 37 | US 7 | 99.22 |
| Econometrics and Quantitative Economics | Lifetime | 915 | US 501 | 99.16 |
| Hematology | Lifetime | 592 | US 301 | 95.53 |
| Pathology and Forensic Medicine | Lifetime | 988 | US 450 | 94.91 |
| Dermatology | Lifetime | 669 | US 273 | 93.76 |
| Geriatrics and Gerontology | Lifetime | 488 | US 188 | 81.23 |
| Oncology | 2021-2025 | 393 | US 168 | 95.50 |
| Blood disorders and treatments | Lifetime | 1 | US 1 | 99.91 |
| Neutropenia and Cancer Infections | Lifetime | 2 | US 2 | 99.95 |
| Hematological disorders and diagnostics | Lifetime | 2 | US 2 | 99.82 |
| Chemotherapy-related skin toxicity | Lifetime | 1 | US 1 | 99.89 |
| Central Venous Catheters and Hemodialysis | Lifetime | 9 | US 7 | 99.78 |
| Economic and Financial Impacts of Cancer | Lifetime | 10 | US 8 | 99.79 |
| Venous Thromboembolism Diagnosis and Management | Lifetime | 44 | US 20 | 99.80 |
| COVID-19 and healthcare impacts | Lifetime | 40 | US 16 | 98.91 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 13 | US 8 | 99.26 |
| Cancer Treatment and Pharmacology | Lifetime | 79 | US 45 | 99.72 |
| Breast Cancer Treatment Studies | Lifetime | 102 | US 57 | 99.65 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 160 | US 79 | 99.46 |
| Biosimilars and Bioanalytical Methods | Lifetime | 74 | US 27 | 98.22 |
| Clinical practice guidelines implementation | Lifetime | 123 | US 38 | 98.28 |
| Breast Lesions and Carcinomas | Lifetime | 171 | US 101 | 98.59 |
| Cancer survivorship and care | Lifetime | 271 | US 142 | 98.07 |
| Cancer Genomics and Diagnostics | Lifetime | 874 | US 463 | 98.46 |
| Bacterial Identification and Susceptibility Testing | Lifetime | 299 | US 126 | 98.39 |
| Lung Cancer Research Studies | Lifetime | 699 | US 297 | 97.68 |
| Childhood Cancer Survivors' Quality of Life | Lifetime | 773 | US 405 | 96.84 |
| Erythropoietin and Anemia Treatment | Lifetime | 198 | US 81 | 96.71 |
| Acute Lymphoblastic Leukemia research | Lifetime | 859 | US 413 | 97.12 |
| Global Cancer Incidence and Screening | Lifetime | 767 | US 408 | 96.74 |
| Cancer Risks and Factors | Lifetime | 468 | US 244 | 96.94 |
| BRCA gene mutations in cancer | Lifetime | 754 | US 391 | 95.61 |
| PARP inhibition in cancer therapy | Lifetime | 530 | US 247 | 94.31 |
| Oral health in cancer treatment | Lifetime | 303 | US 113 | 93.45 |
| Multiple and Secondary Primary Cancers | Lifetime | 824 | US 353 | 92.63 |
| Statistical Methods in Clinical Trials | Lifetime | 569 | US 299 | 94.15 |
| Healthcare cost, quality, practices | Lifetime | 751 | US 407 | 92.23 |
| Intraperitoneal and Appendiceal Malignancies | Lifetime | 751 | US 283 | 92.35 |
| Breast Implant and Reconstruction | Lifetime | 805 | US 392 | 92.48 |
| Cancer-related cognitive impairment studies | Lifetime | 492 | US 268 | 90.86 |
| Meta-analysis and systematic reviews | Lifetime | 764 | US 238 | 91.86 |
| Nausea and vomiting management | Lifetime | 921 | US 297 | 90.71 |
| Case Reports on Hematomas | Lifetime | 429 | US 153 | 80.38 |
| Neutropenia and Cancer Infections | 2021-2025 | 20 | US 10 | 97.93 |
| COVID-19 and healthcare impacts | 2021-2025 | 250 | US 83 | 95.43 |
| Economic and Financial Impacts of Cancer | 2021-2025 | 190 | US 121 | 94.12 |
| Chemotherapy-related skin toxicity | 2021-2025 | 138 | US 52 | 75.74 |
| Healthcare cost, quality, practices | 2021-2025 | 779 | US 337 | 72.44 |
| Blood disorders and treatments | 2021-2025 | 519 | US 124 | 70.38 |
